Year: 2018
Type: review
Abstract: Cardiac autonomic neuropathy (CAN) is a serious com-plication of diabetes mellitus (DM) that is strongly associated with approximately five-fold increased risk of cardiovascular mortality.CAN manifests in a spectrum of things, ranging from resting tachycardia and fixed heart rate (HR) to development of "silent" myocardial infarction.Clinical correlates or risk markers for CAN are age, DM duration, glycemic control, hypertension, and dyslipidemia (DLP), development of other microvascular complications.Established risk factors for CAN are poor glycemic control in type 1 DM and a combination of hypertension, DLP, obesity, and unsatisfactory glycemic control in type 2 DM.Symptomatic manifestations of CAN include sinus tachycardia, exercise intolerance, orthostatic hypotension (OH), abnormal blood pressure (BP) regulation, dizziness, presyncope and syncope, intraoperative cardiovascular instability, asymptomatic myocardial ischemia and infarction.Methods of CAN assessment in clinical practice include assessment of symptoms and signs, cardiovascular reflex tests based on HR and BP, short-term electrocardiography (ECG), QT interval prolongation, HR variability (24 h, classic 24 h Holter ECG), ambulatory BP monitoring, HR turbulence, baroreflex sensitivity, muscle sympathetic nerve activity, catecholamine assessment and cardiovascular sympathetic tests, heart sympathetic imaging.Although it is common complication, the significance of CAN has not been fully appreciated and there are no unified treatment algorithms for today.Treatment is based on early diagnosis, life style changes, optimization of glycemic control and management of cardiovascular risk factors.Pathogenetic treatment of CAN includes: Balanced diet and physical activity; optimization of glycemic control; treatment of DLP; antioxidants, first of all α-lipoic acid (ALA), aldose reductase inhibitors, acetyl-L-carnitine; vitamins, first of all fat-soluble vitamin B1; correction of vascular endothelial dysfunction; prevention and treatment of thrombosis; in severe cases-treatment of OH.The promising methods include prescription of prostacyclin analogues, thromboxane A2 blockers and drugs that contribute into strengthening and/or normalization of Na + , K + -ATPase (phosphodiesterase inhibitor), ALA, dihomo-γ-linolenic acid (DGLA), ω-3 polyunsaturated fatty acids (ω-3 PUFAs), and the simultaneous prescription of ALA, ω-3 PUFAs and DGLA, but the future investigations
Source: World Journal of Diabetes
DOI: 10.4239/wjd.v9.i1.1
Institution: Danylo Halytsky Lviv National Medical University
Language: English
Subfield: Cardiology and Cardiovascular Medicine
Field: Medicine
Domain: Health Sciences
Keywords: diabetes mellitus, risk factors, glycemic control, orthostatic hypotension, silent myocardial infarction, cardiovascular mortality, baroreflex sensitivity, muscle sympathetic nerve activity, alpha-lipoic acid, aldose reductase inhibitors, acetyl-L-carnitine, omega-3 polyunsaturated fatty acids, dihomo-gamma-linolenic acid, endothelial dysfunction, prostacyclin analogues, phosphodiesterase inhibitors, cardiovascular risk factors
Open Access status: diamond
OpenAlex ID: W2783924275
